Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Recruiting now

Conditions studied: Psoriasis

In brief

The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy

Key facts

Study ID

NCT07256015

Run by

Bristol-Myers Squibb

People needed

200

Starts

2025-08-05

Expected to finish

2027-08-05

Last updated by the study team

2025-12-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA)
• Patients have moderate to severe plaque psoriasis
• Patients have signed informed consent form (ICF)

You may not qualify if…

• Simultaneous participation in any interventional study for their moderate-to-severe psoriasis
• Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF

Where it is running

• Azienda Ospedaliera Universitaria Integrata Di Verona — Verona, Verona, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.